reason report
surpris upsid launch agn deal
bottom line report mostli in-lin result
provid extens commentari call
concern oper result pipelin outlook process
toward close acquisit allergan mp updat
model reiter outperform rate maintain
target price believ success close
allergan transact view posit cash flow
exist product suffici substanti de-lev
acquisit abbvi skyrizi strong earli
launch compani seem confid immin pdufa
date key pipelin program upadacitinib call
follow-up discuss us friday manag re-
affirm immun residu opioid litig risk abbott
impact increas feder govern price regul
exposur medicar part import pipelin disclosur
compani discontinu phase ii trial anti-
tau antibodi supranuclear palsi psp
futil rais question valu yet anoth promin
drug develop target dementia increasingli
featur portfolio mani compani
confer call convers afterward abbvi
confirm current timelin close allergan
acquisit suggest dont expect divest skyrizi
divest allergan brazikumab argument brazikumab
develop focus inflammatori bowel diseas wherea skyrizi
approv psoriasi reason would unreason
ftc requir divest skyrizi skyrizi also
develop irrit bowel diseas ibd confirm
prepar applic ftc hsr clearanc
acquisit feedback packag
suggest clearanc may requir multipl applic negoti
re-submiss receiv would disclos
averag dcf price-to-earnings p/sale
net debt total capit
price-to-earnings lt ep growth
compani inform svb leerink llc research
revenu mm dilut ep includ option expens present
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
year price history/av daili volume mil
posit outlook upadacitinib approv anoth import
controversi investor outlook compani
jak inhibitor upadacitinib upa rheumatoid arthriti ra abbvi
reiter expect drug would approv
pdufa date august equivoc whether drug
burden class label infect thromboembol
malign effect differ jak beyond observ
specif upa pivot trial final stage
negoti label upa regard comment mix
signal one hand seem confid approv
less convict avoid class label risk
inform posit perspect grassley-wyden
abbvi manag well inform week senat
financ committe drug price bill debat compani
respons surprisingli posit although point
medicar part less revenu medicar part
us revenu overal revenu compani
suggest believ highest prioriti chang
structur part benefit patient longer expos
cost share high-pric medicin donut hole
propos elimin cost share focus
smooth exposur consum remain out-
of-pocket cost part chang bia plan
innov brand specialti medicin much say
part medicaid
maintain reiter outperform base quarter
result manag commentari disclosur modestli
chang estim compani revenu forecast
increas later year adjust revenu forecast
line consensu higher higher
margin assumpt slightli lower base higher
product cost quarter also suspend share
repurchase estim increas share count forecast
adjust ep forecast lower basi
model prevail peer compani multipl maintain
price target reiter outperform rate abbvi
signific catalyst around corner potenti approv
upadacitinib import issu face compani
progress toward close acquisit allergan expect
hear stock like range-bound next
month given deal arbitrag believ offer compel valu
rang reiter op rate price target
price target per share stock rate outperform
establish independ pharmaceut compani transit
new phase term scale oper effici plan acquisit allergan
earli allergan bring new revenu market categori outsid
current product portfolio allergan aesthet busi one endur franchis
industri unlik advers affect mani risk face tradit
necessarili fan consolid sake see bring
disciplin decis allergan portfolio confid maxim
valu allergan aesthet busi cash flow without disrupt effect
busi unit innov cultur commerci effect ad allergan
dilut abbvi exposur humira posit view offer
compani signific opportun oper effici
synergi alreadi disclos face mani challeng humira franchis rebat
reform patent challeng biosimilar pathway chang patent reform product cash
flow seem rel secur beyond two cornerston hematolog
busi grow strongli sever year least emerg combin
neurosci portfolio gener signific revenu posit cash flow earli
import pipelin program combin compani come abbvi
upadacitinib skyrizi venclexta imbruvica new indic signific increment
opportun probabl allergan neurolog migrain psychiatri schizophrenia
program boost back indic compani long sinc
abandon see combin compani deliv mid-singl digit revenu growth
high singl digit ep growth offer investor attract low doubl digit dividend
growth dividend yield today regard portfolio
particularli innov today view stock compel trade vehicl mid-to-
high reason post-deal valuat rang
revenu beat consensu global humira sale increas sequenti
declin yoy consensu line
forecast ex-u sale declin yoy qoq us imbruvica sale
increas sequenti roughli line consensu forecast
abbvi row profit share imbruvica grew q/q
consensu line forecast hcv revenu quarter viekira
mavyret declin sequenti us ex-u us hcv revenu
come consensu estim expect row hcv revenu
come consensu estim expect androgel sale
lower anticip due gener entri androgel sale
consensu expect respect biggest initi upsid surpris skyrizi
first incomplet quarter sale compar consensu estim
howev approxim half sale channel stock indic demand-driven
sale reason therefor less line expect biggest
disappoint orilissa revenu fell significantli short consensu
similar estim revenu contribut price approxim
global low singl digit us primarili driven ex-u biosimilar competit humira
off-set global volum growth approxim
humira perform stabl surpris total humira revenu beat
consensu us sale match consensu grew yoy wherea
intern sale declin sequenti yoy eros due biosimilar
continu ex-u market suggest updat expect
us market eros close reflect experi ex us
market indic outlook us eros still depend sever factor
interchang us drug price reimburs reform contract etc manag
reiter expect potenti declin ou sale full-year guid
ex-u humira sale approxim line consensu rel
flat compar quarter
continu strong growth heme/onc product report global imbruvica
revenu grow y/i sequenti roughli line
consensu forecast driven continu uptak first-lin cll imbruvica market share
venclexta revenu total repres sequenti growth
line consensu estim forecast continu growth
multipl segment includ relaps refractori front-lin cll also recent approv
orilissa ramp still slower expect fy guidanc lower launch orilissa
elagolix endometriosi sale come lighter
consensu forecast respect manag remain optimist
orilissa long-term potenti adjust sale guidanc
come day expect submit regulatori file women uterin fibroid suffer
heavi menstrual bleed
skyrizi exceed expect sale guidanc increas skyrizi first
quarter perform particularli posit sale significantli beat
consensu estim beat driven rapid uptak first
week launch skyrizi captur in-play patient includ new start
switch major switch come biolog humira
importantli manag believ skyrizi would need divest order obtain ftc
clearanc allergan acquisit howev definit detail regard divestitur plan
expect hsr approv obtain
ep beat consensu total non-gaap expens higher consensu
estim driven primarili higher product sell cost probabl
driven product launch promot expens abbvi tax rate
slightli lower consensu forecast compani guid
expect rate increas increment consist rate time allergan
acquisit like add addit top futur guidanc report non-
gaap ep consensu
guidanc consensu provid guidanc revenu compar
consensu pro forma ep compar consensu
updat ep guidanc consensu increas
adjust ep guidanc consensu
midpoint exhibit insid detail product guidanc
announc earn call
commentari suggest grassley-wyden propos could palat analyst
ask manag view potenti impact grassley-wyden
drug price bill discuss week senat financ committe meet overal
manag suggest support element bill particularli re-
design part benefit elimin co-pay oblig catastroph
coverag threshold indic chang would remov barrier
beneficiari get access need medicin suggest structur benefit
still need chang propos signific step right direct
concern focus front-load natur cap would like
see cost spread year rather concentr one time
conspicu didnt comment cpi price increas restrict suggest part
bill still unreason punit compani sell innov high-pric medicin
suggest implement refer price part nation would requir legisl
perhap form refer price demonstr project could implement
compani stanc commentari gener consist expect outlin
recent note indic part exposur global
sale us sale part less suggest far less expos
part chang peer
exposur opioid litig risk sever analyst ask abbvi
potenti liabil opioid litig involv abbot lab prior co-promot activ purdu
pharma sever member manag includ gener counsel ceo
confirm liabil former activ predecessor
compani liabil limit abbott hospit busi therefor spill
pharmaceut busi spun-off creat
continu strong growth heme/onc product report global imbruvica
revenu grow yoy sequenti roughli line
consensu forecast driven continu uptak first-lin cll imbruvica market share
venclexta revenu total repres sequenti growth
line consensu estim forecast continu growth
multipl segment includ relaps refractori front-lin cll also recent approv
upadacitinib allergan acquisit updat could major catalyst line
prior commentari believ ultim approv label upadacitinib could
signific catalyst particularli light recent black box warn xeljanz
potenti class label updat allergan acquisit includ final
divestitur plan could also provid visibl specif commerci asset drive
futur revenu growth could improv sentiment given ftc perceiv heighten
scrutini toward recent biopharma transact expect see poc data
combin jak-btk inhibitor ra well compani novel antagonist
lupu current view call option
svb leerink estim larg unchang price target maintain reiter
outperform base quarter result manag commentari disclosur
modestli chang estim compani revenu forecast increas
later year mainli account launch trajectori skyrizi slightli stronger
humira sale adjust revenu forecast line recent consensu
higher higher margin assumpt slightli lower base higher
product cost quarter also suspend estim share repurchas
increas share count forecast adjust ep forecast lower
basi model prevail peer compani multipl maintain
price target reiter outperform rate signific catalyst around
corner potenti approv upadacitinib import issu face compani
progress toward close acquisit allergan expect hear
abbvi stock like range-bound next month given deal arbitrag
believ offer compel valu rang reiter op rate price target
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani mid-
term growth tail risk celg averag consensu
ep multipl appli current ep estim give valu
use revenu multipl similar compani consensu
sale appli revenu estim give valu
lastli dcf valuat given wacc termin cash flow growth rate
begin humira biosimilar entri give present valu averag
three method current price target upon complet analysi
quarterli result revisit price target present remain unchang
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi also compani remain highli lever commit grow
dividend reduct forecast ebitda due neg busi trend would place
compani capit alloc strategi dividend growth risk opportun upsid
expect includ stronger-than-expect price volum share humira
emerg tangibl demand underappreci element compani early-to-
mid stage pipelin asset potenti label expans opportun late stage opportun
non-gaap cost good sold
interest expens
abbvi guidanc
late stage pipelin program includ
late stage pipelin program exclud
bispecif mab i/o rova-t non-rova-t
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view
phase trial reuslt newly-diagnos
supplementari approv cll result front-
phase trial front-lin aml
svb leerink llc research compani file
analysi stock price svb leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep celg
svb leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current svb leerink dcf marketed/l stage program
sourc svb leerink llc estim compani file factset
